查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1884037

细菌疫苗市场规模、占有率、成长及全球产业分析：依类型、应用和地区划分的洞察与预测（2024-2032 年）

Bacterial Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 170 Pages | 商品交期: 请询问到货日

价格

细菌疫苗市场成长因素

由于细菌感染发生率上升、疫苗技术进步以及预防保健意识增强，全球细菌疫苗市场正经历强劲增长。 2024 年，该市场价值为 272.3 亿美元，预计 2025 年将成长至 296.8 亿美元，到 2032 年将达到 626.6 亿美元，呈现强劲的成长趋势。 2024 年，北美市场占主导地位，占全球市场占有率的 55.67%。这得归功于广泛的疫苗接种计划、大量的医疗保健支出以及强大的研发基础设施。

市场动态与推动因素

细菌疫苗旨在透过刺激免疫系统识别并攻击细菌病原体来保护个体免受细菌感染。白喉、破伤风、百日咳和肺炎球菌感染等细菌性疾病在全球范围内的日益流行，使得对有效疫苗的需求强劲。人口密度增加和人口迁移模式的转变进一步加剧了细菌感染的传播，推动了疫苗接种计划的扩展。

政府主导的措施、宣传活动以及医疗保健投资的增加是推动市场成长的关键因素。例如，标靶细菌疫苗正在癌症免疫疗法等创新应用领域进行研究，这些疗法可以训练免疫系统识别并攻击癌细胞，从而进一步扩大市场潜力。

市场挑战与阻碍因素

监管障碍仍然是细菌疫苗市场面临的主要挑战。疫苗研发涉及漫长的临床试验和审批流程，通常需要 10-15 年，每个产品耗资数百万美元。各国监管要求不尽相同，使得全球审核更加复杂。此外，私部门的定价限制（例如，脑膜炎双球菌疫苗每剂 189.35 美元（美国疾病管制与预防中心，2025 年 6 月））可能会限制获利能力并抑制市场成长。

细菌病原体的复杂性也构成挑战。细菌拥有多种抗原，难以确定哪些抗原能引发持续的免疫反应。这需要对研发进行大量投资，进而影响新产品的上市速度。

市场机会

日益严重的抗菌素抗药性 (AMR) 带来了巨大的成长机会。由于超过 70% 的主要细菌菌株对抗生素具有抗药性，疫苗提供了一种预防性解决方案，可以减少对抗生素的依赖，并减缓抗药性病原体的出现。诸如 CARB-X 等全球资助计画正在大力投资细菌疫苗的研发，凸显了该市场的成长潜力。

市场趋势

一个关键的市场趋势是开发耐热疫苗，这种疫苗可以在 -20°C 至 +40°C 的极端温度下保持稳定。此类创新降低了对冷链物流的依赖，并提高了疫苗的可近性，尤其是在新兴经济体。例如，Stablepharma公司于2025年4月启动了全球首款冷藏细菌疫苗SPVX02的人体试验。耐热疫苗，包括肺炎球菌疫苗和Hib疫苗，作为儿科疫苗，日益受到关注。

细分市场分析

依疫苗类型划分，重组疫苗、结合疫苗和次单位疫苗因其高效性、长期保护作用和简化的生产工艺，在2024年占市场主导地位。灭活疫苗维持第二大市场占有率，并因其稳定性和对免疫功能低下患者的适用性而持续成长。

依给药途径划分，注射疫苗在2024年占市场主导地位，这主要得益于其高效性和政府主导的疫苗接种运动。口服疫苗因其给药方便、安全性高和成本优势，正迅速成为一个快速成长的细分市场。

依年龄组别划分，儿科市场在2024年占主导地位，这主要得益于不断增长的出生人口和广泛的疫苗接种计划，包括DTP3疫苗（预计到2023年全球覆盖率将达到84%：世界卫生组织，2024年7月）。由于细菌感染的日益普遍以及成人疫苗的研发，成人疫苗也备受关注。

依适应症划分，肺炎链球菌感染疫苗占市场主导地位，其次是白喉-破伤风-百日咳疫苗。

区域展望

预计北美市场将在2024年以151.6亿美元的市场规模引领市场，主要得益于免疫接种计画、强大的研发实力和监管支持。欧洲市场也因国家免疫接种计划和集中式疫苗采购系统而保持稳定成长。亚太地区是成长最快的地区，以印度和中国为首，并得到当地疫苗生产商和政府宣传活动的支持。拉丁美洲以及中东和非洲地区也正逐步扩大规模，这得益于联合国儿童基金会-全球疫苗免疫联盟（UNICEF-GAVI）的疫苗接种计划以及耐热疫苗的推广应用。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场推动因素
  • 市场阻碍因素
  • 市场机遇
  • 市场趋势

第四章：主要发现

  • 主要国家/地区主要疾病的发生率/盛行率（2024 年）
  • 主要公司产品线分析
  • 细菌疫苗的技术进步
  • 主要公司新产品发布
  • 主要产业趋势，包括併购和合作

章节5：全球细菌疫苗市场分析、洞察与预测（2019-2032）

  • 依类型划分的市场分析、洞察与预测
    • 重组/结合/次单位疫苗
    • 灭活​​疫苗
    • 减毒活疫苗
    • 类毒素疫苗
    • 其他
  • 依给药途径划分的市场分析、洞察与预测
    • 注射剂
    • 口服剂
  • 依年龄组别划分的市场分析、洞察与预测
    • 儿童
    • 成人
  • 依适应症划分的市场分析、洞察与预测
    • 脑膜炎双球菌感染
    • 肺炎链球菌感染
    • 白喉、破伤风和百日咳
    • 其他
  • 市场分析、洞察与预测 - 依销售管道划分
    • 医院和零售药局
    • 政府供应商
    • 其他
  • 市场分析、洞察与预测 - 依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章：北美细菌疫苗市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 美国
    • 加拿大

第七章：欧洲细菌疫苗市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 斯堪的纳维亚
    • 欧洲其他地区

第八章 亚太地区细菌疫苗市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章 拉丁美洲细菌疫苗市场分析、洞察与预测（2019-2032）

  • 依国家/地区
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第十章：中东和非洲细菌疫苗市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 海湾合作委员会
    • 南非
    • 中东和非洲其他地区

第十一章 竞争分析

  • 全球市占率分析（2024）
  • 公司简介
    • 赛诺菲
    • 葛兰素史克
    • 默克公司 (Merck & Co., Inc.)
    • 巴拉特生技公司 (Bharat Biotech)
    • 辉瑞公司 (Pfizer Inc.)
    • 新兴生物解决方案公司 (Emergent BioSolutions, Inc.)
    • 印度血清研究所 (Serum Institute of India Pvt. Ltd.)
    • 生医公司 (BIO-MED)
Product Code: FBI113652

Growth Factors of bacterial vaccines Market

The global bacterial vaccines market is experiencing robust growth due to rising incidence of bacterial infections, advancements in vaccine technology, and increasing awareness of preventive healthcare. The market was valued at USD 27.23 billion in 2024, projected to grow to USD 29.68 billion in 2025, and expected to reach USD 62.66 billion by 2032, demonstrating a strong upward trajectory. North America dominated the market in 2024, accounting for 55.67% of the global share, supported by widespread vaccination initiatives, substantial healthcare spending, and strong research and development infrastructure.

Market Dynamics and Drivers

Bacterial vaccines are designed to protect individuals from bacterial infections by stimulating the immune system to recognize and combat bacterial pathogens. Rising global prevalence of bacterial diseases such as diphtheria, tetanus, pertussis, and pneumococcal infections has created a strong demand for effective vaccines. Increased population density and migration patterns further contribute to the spread of bacterial infections, encouraging higher adoption of vaccination programs.

Government initiatives, awareness campaigns, and rising healthcare investments are key drivers of growth. For instance, targeted bacterial vaccines are being explored for innovative applications such as cancer immunotherapy, where they train the immune system to identify and attack cancer cells, further expanding market potential.

Market Challenges and Restraints

Regulatory hurdles remain a significant challenge in the bacterial vaccines market. Vaccine development involves lengthy clinical trials and approval timelines, often spanning 10-15 years, with costs running into millions of dollars per product. Regulatory requirements vary across countries, complicating global approvals. Additionally, pricing constraints in the private sector-such as the Meningococcal vaccine cost of USD 189.35 per dose (CDC, June 2025)-may limit profitability, which could restrain market growth.

The complexity of bacterial pathogens also poses challenges. Bacteria possess diverse antigens, making it difficult to identify which antigens will trigger long-lasting immune responses. This requires substantial investment in research and development, impacting the speed of new product introduction.

Market Opportunities

The rise in antimicrobial resistance (AMR) offers lucrative growth opportunities. With over 70% of major bacterial strains exhibiting antibiotic resistance, vaccines provide a preventive solution, reducing reliance on antibiotics and slowing the emergence of drug-resistant pathogens. Global funding initiatives, such as CARB-X, are investing heavily in bacterial vaccine development, highlighting the market's potential for growth.

Trends in the Market

A major trend in the market is the development of thermostable vaccines, capable of remaining stable in extreme temperatures ranging from -20°C to +40°C. Such innovations reduce dependency on cold-chain logistics and increase vaccine accessibility, particularly in emerging economies. For example, Stablepharma initiated human trials for SPVX02, the world's first fridge-free bacterial vaccine, in April 2025. Thermostable vaccines are increasingly being targeted for pediatric vaccines, including pneumococcal and Hib vaccines.

Segmentation Analysis

By type, the recombinant/conjugate/subunit segment dominated in 2024 due to its efficacy, long-term protection, and simplified manufacturing process. The inactivated segment is the second-largest and is growing due to its stability and suitability for immunocompromised individuals.

By route of administration, parenteral vaccines led the market in 2024 because of higher efficacy and government-supported immunization campaigns. Oral vaccines are emerging as a fast-growing segment due to ease of administration, safety, and cost advantages.

By age group, the pediatric segment dominated in 2024, driven by rising birth cohorts and extensive immunization programs, including the DTP3 vaccine, which reached 84% global coverage in 2023 (WHO, July 2024). Adult vaccines are also gaining attention due to rising bacterial infection prevalence and R&D in adult-targeted vaccines.

By indication, pneumococcal disease led the market, followed by diphtheria/tetanus/pertussis vaccines.

Regional Outlook

North America dominated with USD 15.16 billion in 2024, driven by vaccination programs, strong R&D, and regulatory support. Europe is growing steadily with national immunization programs and centralized vaccine procurement systems. Asia Pacific is the fastest-growing region, led by India and China, supported by local vaccine manufacturers and government campaigns. Latin America and the Middle East & Africa are expanding gradually, bolstered by UNICEF and GAVI vaccination initiatives and the adoption of thermostable vaccines.

Competitive Landscape

Key players include Sanofi (France), GSK plc. (U.K.), Merck & Co., Inc. (U.S.), Bharat Biotech (India), Pfizer Inc. (U.S.), Emergent BioSolutions, Inc. (U.S.), and the Serum Institute of India Pvt. Ltd. These companies focus on R&D, strategic partnerships, and global distribution networks. Notable developments include Pfizer's PREVENAR 20 approval in March 2024 and Merck's Capvaxive pneumococcal vaccine approval in June 2024.

Conclusion

With a market size of USD 27.23 billion in 2024, growing to USD 29.68 billion in 2025 and projected to reach USD 62.66 billion by 2032, the bacterial vaccines market is set for strong growth. Driven by rising bacterial disease prevalence, antimicrobial resistance concerns, technological advancements, and expanding immunization programs, the market offers substantial opportunities for vaccine manufacturers, healthcare providers, and public health organizations globally.

Segmentation By Type

  • Recombinant/Conjugate/Subunit
  • Inactivated
  • Live Attenuated
  • Toxoid
  • Others

By Route of Administration

  • Parenteral
  • Oral

By Age Group

  • Pediatrics
  • Adults

By Indication

  • Meningococcal Disease
  • Pneumococcal Disease
  • Diphtheria/Tetanus/Pertussis
  • Others

By Distribution Channel

  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Others

By Geography

  • North America (By Type, Route of Administration, Age Group, Indication, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Type, Route of Administration, Age Group, Indication, Distribution Channel, and Country/Sub-Region)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Type, Route of Administration, Age Group, Indication, Distribution Channel, and Country/Sub-Region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of the Asia Pacific
  • Latin America (By Type, Route of Administration, Age Group, Indication, Distribution Channel, and Country/Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Type, Route of Administration, Age Group, Indication, Distribution Channel, and Country/Sub-Region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Incidence/Prevalence of Key Diseases, By Key Countries/Regions, 2024
  • 4.2. Pipeline Analysis, By Key Players
  • 4.3. Technological Advancements in the Bacterial Vaccines
  • 4.4. New Product Launches, By Key Players
  • 4.5. Key Industry Developments Such as Mergers, Acquisitions, and Partnerships

5. Global Bacterial Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Recombinant/Conjugate/Subunit
    • 5.1.2. Inactivated
    • 5.1.3. Live Attenuated
    • 5.1.4. Toxoid
    • 5.1.5. Others
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Parenteral
    • 5.2.2. Oral
  • 5.3. Market Analysis, Insights and Forecast - By Age Group
    • 5.3.1. Pediatrics
    • 5.3.2. Adolts
  • 5.4. Market Analysis, Insights and Forecast - By Indication
    • 5.4.1. Meningococcal Disease
    • 5.4.2. Pneumococcal Disease
    • 5.4.3. Diphtheria/Tetanus/Pertussis
    • 5.4.4. Others
  • 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.5.1. Hospital & Retail Pharmacies
    • 5.5.2. Government Suppliers
    • 5.5.3. Others
  • 5.6. Market Analysis, Insights and Forecast - By Region
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa

6. North America Bacterial Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Recombinant/Conjugate/Subunit
    • 6.1.2. Inactivated
    • 6.1.3. Live Attenuated
    • 6.1.4. Toxoid
    • 6.1.5. Others
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Parenteral
    • 6.2.2. Oral
  • 6.3. Market Analysis, Insights and Forecast - By Age Group
    • 6.3.1. Pediatrics
    • 6.3.2. Adolts
  • 6.4. Market Analysis, Insights and Forecast - By Indication
    • 6.4.1. Meningococcal Disease
    • 6.4.2. Pneumococcal Disease
    • 6.4.3. Diphtheria/Tetanus/Pertussis
    • 6.4.4. Others
  • 6.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.5.1. Hospital & Retail Pharmacies
    • 6.5.2. Government Suppliers
    • 6.5.3. Others
  • 6.6. Market Analysis, Insights and Forecast - By Country
    • 6.6.1. U.S.
    • 6.6.2. Canada

7. Europe Bacterial Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Recombinant/Conjugate/Subunit
    • 7.1.2. Inactivated
    • 7.1.3. Live Attenuated
    • 7.1.4. Toxoid
    • 7.1.5. Others
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Parenteral
    • 7.2.2. Oral
  • 7.3. Market Analysis, Insights and Forecast - By Age Group
    • 7.3.1. Pediatrics
    • 7.3.2. Adolts
  • 7.4. Market Analysis, Insights and Forecast - By Indication
    • 7.4.1. Meningococcal Disease
    • 7.4.2. Pneumococcal Disease
    • 7.4.3. Diphtheria/Tetanus/Pertussis
    • 7.4.4. Others
  • 7.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.5.1. Hospital & Retail Pharmacies
    • 7.5.2. Government Suppliers
    • 7.5.3. Others
  • 7.6. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 7.6.1. U.K.
    • 7.6.2. Germany
    • 7.6.3. France
    • 7.6.4. Spain
    • 7.6.5. Italy
    • 7.6.6. Scandinavia
    • 7.6.7. Rest of Europe

8. Asia Pacific Bacterial Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Recombinant/Conjugate/Subunit
    • 8.1.2. Inactivated
    • 8.1.3. Live Attenuated
    • 8.1.4. Toxoid
    • 8.1.5. Others
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Parenteral
    • 8.2.2. Oral
  • 8.3. Market Analysis, Insights and Forecast - By Age Group
    • 8.3.1. Pediatrics
    • 8.3.2. Adolts
  • 8.4. Market Analysis, Insights and Forecast - By Indication
    • 8.4.1. Meningococcal Disease
    • 8.4.2. Pneumococcal Disease
    • 8.4.3. Diphtheria/Tetanus/Pertussis
    • 8.4.4. Others
  • 8.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.5.1. Hospital & Retail Pharmacies
    • 8.5.2. Government Suppliers
    • 8.5.3. Others
  • 8.6. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. Australia
    • 8.6.5. Southeast Asia
    • 8.6.6. Rest of Asia Pacific

9. Latin America Bacterial Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Recombinant/Conjugate/Subunit
    • 9.1.2. Inactivated
    • 9.1.3. Live Attenuated
    • 9.1.4. Toxoid
    • 9.1.5. Others
  • 9.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.2.1. Parenteral
    • 9.2.2. Oral
  • 9.3. Market Analysis, Insights and Forecast - By Age Group
    • 9.3.1. Pediatrics
    • 9.3.2. Adolts
  • 9.4. Market Analysis, Insights and Forecast - By Indication
    • 9.4.1. Meningococcal Disease
    • 9.4.2. Pneumococcal Disease
    • 9.4.3. Diphtheria/Tetanus/Pertussis
    • 9.4.4. Others
  • 9.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.5.1. Hospital & Retail Pharmacies
    • 9.5.2. Government Suppliers
    • 9.5.3. Others
  • 9.6. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 9.6.1. Brazil
    • 9.6.2. Mexico
    • 9.6.3. Rest of Latin America

10. Middle East & Africa Bacterial Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. Recombinant/Conjugate/Subunit
    • 10.1.2. Inactivated
    • 10.1.3. Live Attenuated
    • 10.1.4. Toxoid
    • 10.1.5. Others
  • 10.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.2.1. Parenteral
    • 10.2.2. Oral
  • 10.3. Market Analysis, Insights and Forecast - By Age Group
    • 10.3.1. Pediatrics
    • 10.3.2. Adolts
  • 10.4. Market Analysis, Insights and Forecast - By Indication
    • 10.4.1. Meningococcal Disease
    • 10.4.2. Pneumococcal Disease
    • 10.4.3. Diphtheria/Tetanus/Pertussis
    • 10.4.4. Others
  • 10.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.5.1. Hospital & Retail Pharmacies
    • 10.5.2. Government Suppliers
    • 10.5.3. Others
  • 10.6. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 10.6.1. GCC
    • 10.6.2. South Africa
    • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles
    • 11.2.1. Sanofi
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. GSK plc.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Merck & Co., Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Bharat Biotech
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Pfizer Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Emergent BioSolutions, Inc.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Serum Institute of india Pvt. Ltd.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. BIO-MED
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Bacterial Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 2: Global Bacterial Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 3: Global Bacterial Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2033
  • Table 4: Global Bacterial Vaccines Market Revenue (USD billion) Forecast, by Indication, 2019-2034
  • Table 5: Global Bacterial Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 6: Global Bacterial Vaccines Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 7: North America Bacterial Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 8: North America Bacterial Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 9: North America Bacterial Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 10: North America Bacterial Vaccines Market Revenue (USD billion) Forecast, by Indication, 2019-2032
  • Table 11: North America Bacterial Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 12: North America Bacterial Vaccines Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 13: Europe Bacterial Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 14: Europe Bacterial Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 15: Europe Bacterial Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 16: Europe Bacterial Vaccines Market Revenue (USD billion) Forecast, by Indication, 2019-2032
  • Table 17: Europe Bacterial Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 18: Europe Bacterial Vaccines Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 19: Asia Pacific Bacterial Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 20: Asia Pacific Bacterial Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 21: Asia Pacific Bacterial Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 22: Asia Pacific Bacterial Vaccines Market Revenue (USD billion) Forecast, by Indication, 2019-2032
  • Table 23: Asia Pacific Bacterial Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 24: Asia Pacific Bacterial Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 25: Latin America Bacterial Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 26: Latin America Bacterial Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 27: Latin America Bacterial Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 28: Latin America Bacterial Vaccines Market Revenue (USD billion) Forecast, by Indication, 2019-2032
  • Table 29: Latin America Bacterial Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 30: Latin America Bacterial Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 31: Middle East & Africa Bacterial Vaccines Market Revenue (USD billion) Forecast, by Type, 2019-2032
  • Table 32: Middle East & Africa Bacterial Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 33: Middle East & Africa Bacterial Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2019-2032
  • Table 34: Middle East & Africa Bacterial Vaccines Market Revenue (USD billion) Forecast, by Indication, 2019-2032
  • Table 35: Middle East & Africa Bacterial Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 36: Middle East & Africa Bacterial Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

List of Figures

  • Figure 1: Global Bacterial Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
  • Figure 2: Global Bacterial Vaccines Market Value Share (%), by Type, 2024 & 2032
  • Figure 3: Global Bacterial Vaccines Market Value Share (%), by Route of Administration, 2024 & 2032
  • Figure 4: Global Bacterial Vaccines Market Value Share (%), by Age Group, 2024 & 2033
  • Figure 5: Global Bacterial Vaccines Market Value Share (%), by Indication, 2024 & 2034
  • Figure 6: Global Bacterial Vaccines Market Value Share (%), by Distribution Channel, 2024 & 2032
  • Figure 7: Global Bacterial Vaccines Market Value Share (%), by Region, 2024 & 2032
  • Figure 8: North America Bacterial Vaccines Market Value (USD billion), by Type, 2024 & 2032
  • Figure 9: North America Bacterial Vaccines Market Value Share (%), by Type, 2024
  • Figure 10: North America Bacterial Vaccines Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 11: North America Bacterial Vaccines Market Value Share (%), by Route of Administration, 2024
  • Figure 12: North America Bacterial Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 13: North America Bacterial Vaccines Market Value Share (%), by Age Group, 2024
  • Figure 14: North America Bacterial Vaccines Market Value (USD billion), by Indication, 2024 & 2032
  • Figure 15: North America Bacterial Vaccines Market Value Share (%), by Indication, 2024
  • Figure 16: North America Bacterial Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 17: North America Bacterial Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 18: North America Bacterial Vaccines Market Value (USD billion), By Country, 2024 & 2032
  • Figure 19: North America Bacterial Vaccines Market Value Share (%), By Country, 2024
  • Figure 20: Europe Bacterial Vaccines Market Value (USD billion), by Type, 2024 & 2032
  • Figure 21: Europe Bacterial Vaccines Market Value Share (%), by Type, 2024
  • Figure 22: Europe Bacterial Vaccines Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 23: Europe Bacterial Vaccines Market Value Share (%), by Route of Administration, 2024
  • Figure 24: Europe Bacterial Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 25: Europe Bacterial Vaccines Market Value Share (%), by Age Group, 2024
  • Figure 26: Europe Bacterial Vaccines Market Value (USD billion), by Indication, 2024 & 2032
  • Figure 27: Europe Bacterial Vaccines Market Value Share (%), by Indication, 2024
  • Figure 28: Europe Bacterial Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 29: Europe Bacterial Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 30: Europe Bacterial Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 31: Europe Bacterial Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 32: Asia Pacific Bacterial Vaccines Market Value (USD billion), by Type, 2024 & 2032
  • Figure 33: Asia Pacific Bacterial Vaccines Market Value Share (%), by Type, 2024
  • Figure 34: Asia Pacific Bacterial Vaccines Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 35: Asia Pacific Bacterial Vaccines Market Value Share (%), by Route of Administration, 2024
  • Figure 36: Asia Pacific Bacterial Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 37: Asia Pacific Bacterial Vaccines Market Value Share (%), by Age Group, 2024
  • Figure 38: Asia Pacific Bacterial Vaccines Market Value (USD billion), by Indication, 2024 & 2032
  • Figure 39: Asia Pacific Bacterial Vaccines Market Value Share (%), by Indication, 2024
  • Figure 40: Asia Pacific Bacterial Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 41: Asia Pacific Bacterial Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 42: Asia Pacific Bacterial Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 43: Asia Pacific Bacterial Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 44: Latin America Bacterial Vaccines Market Value (USD billion), by Type, 2024 & 2032
  • Figure 45: Latin America Bacterial Vaccines Market Value Share (%), by Type, 2024
  • Figure 46: Latin America Bacterial Vaccines Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 47: Latin America Bacterial Vaccines Market Value Share (%), by Route of Administration, 2024
  • Figure 48: Latin America Bacterial Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 49: Latin America Bacterial Vaccines Market Value Share (%), by Age Group, 2024
  • Figure 50: Latin America Bacterial Vaccines Market Value (USD billion), by Indication, 2024 & 2032
  • Figure 51: Latin America Bacterial Vaccines Market Value Share (%), by Indication, 2024
  • Figure 52: Latin America Bacterial Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 53: Latin America Bacterial Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 54: Latin America Bacterial Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 55: Latin America Bacterial Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 56: Middle East & Africa Bacterial Vaccines Market Value (USD billion), by Type, 2024 & 2032
  • Figure 57: Middle East & Africa Bacterial Vaccines Market Value Share (%), by Type, 2024
  • Figure 58: Middle East & Africa Bacterial Vaccines Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 59: Middle East & Africa Bacterial Vaccines Market Value Share (%), by Route of Administration, 2024
  • Figure 60: Middle East & Africa Bacterial Vaccines Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 61: Middle East & Africa Bacterial Vaccines Market Value Share (%), by Age Group, 2024
  • Figure 62: Middle East & Africa Bacterial Vaccines Market Value (USD billion), by Indication, 2024 & 2032
  • Figure 63: Middle East & Africa Bacterial Vaccines Market Value Share (%), by Indication, 2024
  • Figure 64: Middle East & Africa Bacterial Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 65: Middle East & Africa Bacterial Vaccines Market Value Share (%), by Distribution Channel, 2024
  • Figure 66: Middle East & Africa Bacterial Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 67: Middle East & Africa Bacterial Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 68: Global Bacterial Vaccines Market Share (%), By Company, 2024